Geisinger Health taps new CEO
Terry Gilliland will replace Jaewon Ryu, who will lead Risant Health.
Uncategorized
BD starts trial of vascular covered stent in peripheral arterial disease
Peripheral vascular disease is one of six key platforms that BD is targeting for growth.
BD starts trial of vascular covered stent in peripheral arterial disease Read More »
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
MyMD Pharmaceuticals, Inc. today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (“Listing Rule”).
Grace Science, LLC Announces First Patient Treated in Phase 1/2/3 Trial of GS-100, an AAV9 Gene Therapy for NGLY1 Deficiency
Grace Science, LLC announced today that the first patient was dosed in an open-label Phase 1/2/3 clinical trial of GS-100, an AAV9 gene replacement therapy for the treatment of NGLY1 Deficiency.
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area
Today the Foster City-based company is the second-largest biotech employer in the Bay Area.
Gilead Sciences CEO on Company’s Evolution and Commitment to the Bay Area Read More »
Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing
Twist Bioscience Corporation today announced European Union (EU) in vitro diagnostic regulations (IVDR) compliant Twist Precision Dx next-generation sequencing (NGS) Products.
Haemonetics Announces Definitive Agreement to Acquire Attune Medical
Haemonetics Corporation announced that it has entered into a definitive agreement to acquire privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device, the only FDA-cleared temperature regulation device indicated for esophageal protection during radiofrequency cardiac ablation procedures.
Haemonetics Announces Definitive Agreement to Acquire Attune Medical Read More »
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407.
Haz esto si quieres vivir más de 100 años
La búsqueda de la longevidad y una vida saludable es un objetivo compartido por muchas personas en todo el mundo. A medida que la ciencia y la medicina continúan avanzando, cada vez más personas están buscando formas de prolongar su vida y disfrutar de una vejez activa y …
Las aplicaciones médicas de la realidad aumentada
La realidad aumentada (RA) ha emergido como una herramienta innovadora con el potencial de revolucionar la prestación de atención médica. Desde la formación de cirujanos hasta la planificación de procedimientos quirúrgicos y la mejora de la educación …
Las aplicaciones médicas de la realidad aumentada Read More »